These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28715811)

  • 41. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema.
    Gerendas BS; Prager S; Deak G; Simader C; Lammer J; Waldstein SM; Guerin T; Kundi M; Schmidt-Erfurth UM
    Br J Ophthalmol; 2018 Feb; 102(2):195-203. PubMed ID: 28724636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema.
    Chatziralli I; Chatzipantelis A; Dimitriou E; Mpourouki E; Theodossiadis G; Theodossiadis P
    Clin Exp Optom; 2018 May; 101(3):397-399. PubMed ID: 29134696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
    Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
    Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data.
    Gonzalez VH; Campbell J; Holekamp NM; Kiss S; Loewenstein A; Augustin AJ; Ma J; Ho AC; Patel V; Whitcup SM; Dugel PU
    Am J Ophthalmol; 2016 Dec; 172():72-79. PubMed ID: 27644589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes.
    Zucchiatti I; Bandello F
    Dev Ophthalmol; 2017; 60():63-70. PubMed ID: 28427066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
    Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA: Impact on Clinical Outcomes.
    Stewart S; Yeong JL; Virgili G; Azuara-Blanco A; Lois N
    Retina; 2020 May; 40(5):919-927. PubMed ID: 30789463
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital.
    Battaglia Parodi M; Romano F; Arrigo A; Sacchi R; Scanzi G; Ferri C; Bandello F
    Eur J Ophthalmol; 2020 Nov; 30(6):1461-1466. PubMed ID: 31617403
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
    Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH
    Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of serous retinal detachment on the efficacy of ranibizumab in diabetic macular oedema.
    Qu-Knafo LM; Fajnkuchen F; Sarda V; Boubaya M; Levy V; Chaine G; Giocanti-Auregan A
    Acta Ophthalmol; 2017 Aug; 95(5):e434-e435. PubMed ID: 26823130
    [No Abstract]   [Full Text] [Related]  

  • 54. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.
    Bressler SB; Glassman AR; Almukhtar T; Bressler NM; Ferris FL; Googe JM; Gupta SK; Jampol LM; Melia M; Wells JA;
    Am J Ophthalmol; 2016 Apr; 164():57-68. PubMed ID: 26802783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
    Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
    Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms.
    Mori K; Yoshida S; Kobayashi Y; Ishikawa K; Nakao S; Hisatomi T; Haruta M; Isihibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):735-741. PubMed ID: 31960130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
    Seo KH; Yu SY; Kim M; Kwak HW
    Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12-month prospective clinical trial.
    Blindbaek SL; Peto T; Grauslund J
    Acta Ophthalmol; 2020 Jun; 98(4):353-359. PubMed ID: 31654501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
    Wiley HE; Thompson DJ; Bailey C; Chew EY; Cukras CA; Jaffe GJ; Lee RW; Loken EK; Meyerle CB; Wong W; Ferris FL
    Ophthalmology; 2016 Apr; 123(4):841-9. PubMed ID: 26875003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.